Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)
Nivolumab plus lenvatinib had a manageable safety in advanced BTC, but its efficacy in the second-line treatment was limited.
Authors
- M. Sasaki
- Masafumi Ikeda (ORCID: https://orcid.org/0000-0002-4050-2086)
- F. Nagashima
- J. Mizusawa
- A. Kasuga
- C. Morizane
- S. Kobayashi
- Makoto Ueno (ORCID: https://orcid.org/0000-0003-4480-0029)
- Junji Furuse (ORCID: https://orcid.org/0000-0003-0663-6117)
- M. Ozaka
- Tomoko Kataoka (ORCID: https://orcid.org/0000-0003-4468-2632)
- A. Ohba
- Naohiro Okano (ORCID: https://orcid.org/0000-0002-4098-5217)
- Hiroshi Imaoka (ORCID: https://orcid.org/0000-0003-0584-0095)
- Takuji Okusaka (ORCID: https://orcid.org/0000-0003-1729-807X)
- Y. Nagasaka
Institutions
- Kyorin University (JP)
- Kanagawa Prefectural Hospital Organization (JP)
- National Cancer Center Hospital East (JP)
- Japan Clinical Cancer Research Organization (JP)
- Japanese Foundation For Cancer Research (JP)
- Kanagawa Cancer Center
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103919
- Citations
- 8
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.58
Funders
- AstraZeneca
- Taiho Pharmaceutical
- Eisai
- European Society for Medical Oncology
- Yakult Honsha
- Ono Pharmaceutical